Brief: Passage Bio Doses First Patient In Global Clinical Trial Of PBFT02 Gene Therapy For Frontotemporal Dementia With Granulin Mutations

Passage Bio

11/08/2022 12:28

Aug 11 (Reuters) - Passage Bio Inc  PASG.O :
    * PASSAGE BIO DOSES FIRST PATIENT IN GLOBAL CLINICAL TRIAL
OF
PBFT02 GENE THERAPY FOR FRONTOTEMPORAL DEMENTIA WITH GRANULIN
MUTATIONS

Source text for Eikon:  ID:nGNX1sDdm4 
Further company coverage:  PASG.O